Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice
MetadataShow full item record
In this study, we examined the in-vivo characteristics of a novel microencapsulated thalidomide formulation in a murine model of experimental Crohn's disease. Crohn's disease was induced with a single intra-colonic injection of 120 mg/kg of bodyweight of 2,5,6-trinitrobenzene sulfonic acid (TNBS) dissolved in 30% ethanol in Balb/c mice. Level of tumor necrosis factor alpha (TNF-), interleukin one beta (IL-1), interleukin 6 (IL-6) and nitric oxide (NO) were measured in tissue homogenate. Moreover, myeloperoxidase (MPO) activity was determined to assess the extent of neutrophil infiltration. Dose response study showed that treating the mice with microencapsulated thalidomide (100 mg/kg of bodyweight) for two weeks significantly decreased the degree of intestinal inflammation related to Crohn’s disease. Higher and lower doses (0, 25, 50 and 200 mg/kg of bodyweight) did not exhibit comparable effects. The present study validates the success of alginate-poly-L-lysine-alginate (APA) microcapsules containing thalidomide in reducing colonic inflammation, and proposes a potential remedy for Crohn’s disease.
Showing items related by title, author, creator and subject.
Qiao, J.; Wu, Yong Hong; Wu, X.; Liu, Y.; Li, X.; Ju, W.; Qi, K.; Li, D.; Gardiner, E.; Andrews, R.; Zeng, L.; Xu, K. (2017)Increased risk of thromboembolism and platelet hyperreactivity has been reported in patients receiving thalidomide therapy. Whether thalidomide induces platelet activation directly or through other factors remains unclear. ...
The epidemiology of anemia in pediatric inflammatory bowel disease: Prevalence and associated factors at diagnosis and follow-up and the impact of exclusive enteral nutritionGerasimidis, K.; Barclay, A.; Papangelou, A.; Missiou, D.; Buchanan, E.; Tracey, C.; Tayler, R.; Russell, R.; Edwards, Christine; McGrogan, P. (2013)Background: Anemia is poorly studied in pediatric inflammatory bowel disease. This study explored the epidemiology and associated factors of anemia at diagnosis, after 1 year, and during treatment with exclusive enteral ...
Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenibWoo, K.; Stewart, S.; Kong, G.; Finch-Edmondson, M.; Dwyer, B.; Yeung, S.; Abraham, L.; Kampmann, S.; Diepeveen, L.; Passman, A.; Elsegood, Caryn; Tirnitz-Parker, Nina; Callus, B.; Olynyk, J.; Yeoh, G. (2016)© 2016 Elsevier Masson SASBackground & aims The availability of non-tumorigenic and tumorigenic liver progenitor cell (LPC) lines affords a method to screen putative anti-liver cancer agents to identify those that are ...